KNIGHT THERAPEUTICS news, videos and press releases - Page 2
For more news please use our advanced search feature.
KNIGHT THERAPEUTICS - More news...
KNIGHT THERAPEUTICS - More news...
- Knight Therapeutics Reports First Quarter 2021 Results
- Knight Therapeutics Announces Leadership Change
- Knight Therapeutics to Acquire Regional Rights to Exelon®
- Knight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor Conference
- Knight Therapeutics Reports Fourth Quarter and Year End 2020 Results
- Knight Announces Filing of Final Base Shelf Prospectus
- Knight Announces Filing of Preliminary Base Shelf Prospectus
- Notice of Knight Therapeutics' Third Quarter 2020 Results Conference Call
- Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
- Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY®
- Knight Therapeutics Reports Second Quarter 2020 Results
- Knight Therapeutics Reports First Quarter 2020 Results
- Knight Therapeutics Inc. announces voting results from the Annual Meeting
- Notice of Knight Therapeutics' First Quarter 2020 Results Conference Call
- Knight Therapeutics Inc. Announces Further Update on Extension of First Quarter 2020 Filings due to COVID-19
- Knight Therapeutics Inc. Announces Extension of First Quarter 2020 Filings due to COVID-19
- Knight Announces the Re-Launch of Trelstar® in Canada
- Notice of Knight Therapeutics' Fourth Quarter 2019 Results Conference Call and update due to COVID-19 pandemic
- Knight Announces Closing of Separation Agreement
- Knight and TherapeuticsMD Announce Filing of New Drug Submission for Bijuva® in Canada
- Notice of Knight Therapeutics' Third Quarter 2019 Results Conference Call
- Knight and TherapeuticsMD Announce Filing of New Drug Submission for Joyesta™ in Canada
- Medison Urges Knight Therapeutics and Jonathan Goodman to Aggressively Pursue Opportunities Created by Distressed Opioid Case Targets
- Knight Therapeutics Reports Second Quarter 2019 Results
- Knight Announces Early Warning Filing Regarding Disposition of Shares of Crescita
- Notice of Knight Therapeutics' Second Quarter 2019 Results Conference Call
- Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight Therapeutics
- Knight to Present at the Raymond James Life Sciences and MedTech Conference in New York City
- Knight to Present at the Jefferies 2019 Global Healthcare Conference in New York City
- Notice of Knight Therapeutics' First Quarter 2019 Results Conference Call
